Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements

NCT ID: NCT02107924

Last Updated: 2014-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to gather information on the use of Stimulan, the surgery, and anitbiotics to whetether the APPI has decreased or shown improvement when compared to study participants who did not receive Stimulan during their revision total knee replacement surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Total Knee Replacment Infection Stimulan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APPI of TKR-Stimulan

Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin

APPI of TKR-Stimulan

Intervention Type PROCEDURE

APPI of TKR-historical

Surgery 2.4 G Tobramycin 2.0 G Vancomycin

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APPI of TKR-Stimulan

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stimulan Tobramycin Vancomycin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* APPI within 28 days of primary TKR
* Acute hematogenous infection within 4 weeks of symptoms

Exclusion Criteria

* Exposed prosthesis
* Infection occuring in revised joints
* Poly articular infections
* have allergies to tobramycin or Vancomycin
* previous chronic infections in or around any ipsilateral extremity trauma or implants
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Methodist Hospital Research Institute

OTHER

Sponsor Role collaborator

Michael Muldoon, M.D.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Muldoon, M.D.

Co-Sponsor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael P Muldoon, MD

Role: PRINCIPAL_INVESTIGATOR

Sharp HealthCare

David R Lionberger, MD

Role: PRINCIPAL_INVESTIGATOR

Southwest Orthopedic Group, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southwest Orthopedic Group, LLP

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, Garvin KL, Mont MA, Wongworawat MD, Zalavras CG. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011 Nov;469(11):2992-4. doi: 10.1007/s11999-011-2102-9. No abstract available.

Reference Type BACKGROUND
PMID: 21938532 (View on PubMed)

Mortazavi SM, Vegari D, Ho A, Zmistowski B, Parvizi J. Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure. Clin Orthop Relat Res. 2011 Nov;469(11):3049-54. doi: 10.1007/s11999-011-2030-8.

Reference Type BACKGROUND
PMID: 21866421 (View on PubMed)

Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J. Infection control rate of irrigation and debridement for periprosthetic joint infection. Clin Orthop Relat Res. 2011 Nov;469(11):3043-8. doi: 10.1007/s11999-011-1910-2.

Reference Type BACKGROUND
PMID: 21553171 (View on PubMed)

Gardner J, Gioe TJ, Tatman P. Can this prosthesis be saved?: implant salvage attempts in infected primary TKA. Clin Orthop Relat Res. 2011 Apr;469(4):970-6. doi: 10.1007/s11999-010-1417-2.

Reference Type BACKGROUND
PMID: 20544317 (View on PubMed)

Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ. A two-stage retention debridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res. 2010 Aug;468(8):2029-38. doi: 10.1007/s11999-010-1293-9.

Reference Type BACKGROUND
PMID: 20224958 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1112-0211

Identifier Type: -

Identifier Source: org_study_id